Crinetics Pharmaceuticals, INC Form 4 insider transactions

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold 5,000 shares of common stock for $41.81 per share.

Crinetics Pharmaceuticals' President and CEO, Richard Scott Struthers, sold 4,000 shares of common stock for $180,000 through a pre-arranged Rule 10b5-1 trading plan.

Crinetics Pharmaceuticals Director Matthew K. Fust exercised stock options and subsequently sold a portion of his common stock holdings for a significant profit, as per a pre-arranged trading plan.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and sold 5,000 shares of common stock under a pre-arranged trading plan.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, sold 30,000 shares of common stock for $30.43 per share after exercising options.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, sold 6,492 shares of common stock for $29.18 per share.

Crinetics Pharmaceuticals' Chief Scientific Officer, Stephen F. Betz, reported the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals, Inc. Director Stephanie Okey was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation, aligning her interests with shareholders.

Crinetics Pharmaceuticals, Inc. Director Caren Deardorf was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation, increasing her beneficial ownership.

Crinetics Pharmaceuticals, Inc. Director Rogerio Vivaldi Coelho was granted 6,900 restricted stock units and 10,350 stock options as part of his compensation, aligning his interests with shareholders.

Matthew K. Fust, a Director at Crinetics Pharmaceuticals, Inc. (CRNX), reported the acquisition of 6,900 restricted stock units and 10,350 stock options as part of his compensation.

Camille L. Bedrosian, a Director at Crinetics Pharmaceuticals, Inc., was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation.

Crinetics Pharmaceuticals, Inc. Director Weston Nichols acquired 6,900 restricted stock units and 10,350 stock options on June 11, 2025, as reported in a recent SEC Form 4 filing.

Crinetics Pharmaceuticals, Inc. Director Wendall Wierenga acquired 6,900 restricted stock units and 10,350 stock options on June 11, 2025, aligning personal interests with long-term company performance.

Richard Scott Struthers, President & CEO of Crinetics Pharmaceuticals, reports gifting 90,400 shares of common stock to both direct and indirect beneficiaries on May 14, 2025.

Crinetics Pharmaceuticals' CEO, Richard Scott Struthers, exercised stock options and reported changes in his beneficial ownership of company stock, including holdings through family trusts and his spouse.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Jeff Knight, COO of Crinetics Pharmaceuticals, sold shares of common stock on March 19, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold shares of common stock on March 19, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Crinetics Pharmaceuticals' CEO, Richard Scott Struthers, sold shares of common stock on March 19, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Tobin Schilke, CFO of Crinetics Pharmaceuticals, reports the acquisition of 52,000 shares of common stock and options to purchase 80,000 shares.

Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reports acquisition of stock and options, including restricted stock units and stock options, as per Form 4 filing.

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, reports acquisition of common stock and stock options.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, acquired stock options and restricted stock units on February 20, 2025.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports acquiring 43,000 shares of common stock and options to purchase 65,000 shares.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold 5,000 shares of common stock on February 3, 2025, as part of a pre-arranged trading plan.

Isabel Kalofonos, Chief Commercial Officer of Crinetics Pharmaceuticals, acquired 100,000 stock options on January 10, 2025.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, exercised stock options on December 16, 2024.

Crinetics Pharmaceuticals CEO Richard Scott Struthers sold 10,000 shares of common stock at an average price of $57.57 per share under a pre-arranged 10b5-1 trading plan.